¹²⁵I brachytherapy combined with chemotherapy of advanced non-small cell lung cancer

【摘要】 This study was to evaluate effect of ¹²⁵I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer（NSCLC）. Patients with NSCLC in stages III to IV were divided into two groups: Group A（n = 27） received ¹²⁵I brachytherapy combined with gemcitabine and cisplatin（GP） chemotherapy, and Group B（n = 27） received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively（P < 0.05）. For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively,with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months（P > 0.05）. The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B（P > 0.05）.In conclusion, ¹²⁵I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.更多还原

【Abstract】 This study was to evaluate effect of ¹²⁵I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer（NSCLC）. Patients with NSCLC in stages III to IV were divided into two groups: Group A（n = 27） received ¹²⁵I brachytherapy combined with gemcitabine and cisplatin（GP） chemotherapy, and Group B（n = 27） received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively（P < 0.05）. For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively,with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months（P > 0.05）. The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B（P > 0.05）.In conclusion, ¹²⁵I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.更多还原